Infectious disease experts are ratcheting up their watchfulness of the H5N1 influenza virus. That’s because the strain of “bird flu” has continued turning up in domestic livestock.
STS risk calculators are known as a go-to resource for cardiologists, surgeons and any other healthcare providers who manage the care of heart patients.
The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.
Infectious disease experts are ratcheting up their watchfulness of the H5N1 influenza virus. That’s because the strain of “bird flu” has continued turning up in domestic livestock.
![An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.](/sites/default/files/styles/stack_views/public/2024-04/screen_shot_2024-04-26_at_10.55.10_am.png.webp?itok=eF1mw-vN)